Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646860 | 0.87 | ESR1 (0.32) | KMT2ASMN1; SMN2CYP1A2CYP2C19ESR1 | |
| SCHEMBL31474902 | 0.85 | MAPK1 (0.35) | KMT2ASMN1; SMN2CYP1A2CYP2C19MAPK1 | |
| SCHEMBL31474901 | 0.85 | MAPK1 (0.35) | KMT2ASMN1; SMN2CYP1A2CYP2C19MAPK1 | |
| SCHEMBL31474903 | 0.85 | MAPK1 (0.35) | KMT2ASMN1; SMN2CYP1A2CYP2C19MAPK1 | |
| SCHEMBL317623 | 0.85 | MAPK1 (0.35) | KMT2ASMN1; SMN2CYP1A2CYP2C19MAPK1 | |
| SCHEMBL8906739 | 0.82 | MMP1 (0.39) | KMT2AMEN1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL29935686 | 0.82 | HTR7 (0.33) | KMT2AMEN1SMN1; SMN2LMNATSHR | |
| SCHEMBL9349704 | 0.82 | CYP2C9 (0.34) | LMNACYP2C19CYP2C9MAPTGAA | |
| SCHEMBL3874638 | 0.81 | THRB (0.34) | KMT2ASMN1; SMN2HPGDNPC1MAPT | |
| SCHEMBL8907659 | 0.80 | KMT2A (0.36) | KMT2ASMN1; SMN2LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10512700-B2 | Radiohalide-labeled targeted diagnostics and therapeutics | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-12-24 | — | — | US | disclosed |
| EP-2745850-B1 | NANO-PARTICLES FOR INTERNAL RADIATION THERAPY OF INVOLVED AREA, AND THERAPY SYSTEM | SHIMADZU CORP (JP) | 2018-05-16 | — | — | EP | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170266327-A1 | RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-21 | — | — | US | disclosed |
| CN-106573951-A | Micro saponin analogue, synthesis and use thereof | 索隆-基特林癌症研究协会 | 2017-04-19 | — | — | CN | disclosed |
| US-5746997-A | Radiohalogenation of oligonucleotides via trialkylstannylaryl conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5609848-A | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| US-5213787-A | RADIOHALOGENATED SMALL MOLECULES FOR PROTEIN LABELING | NEORX CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0203764-B1 | RADIOHALOGENATED SMALL MOLECULES FOR PROTEIN LABELING | NEORX CORPORATION (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5102651-A | PROCESS FOR ISOLATION AND RADIOLABELING OF PHARMACEUTICALS WITH ISOTOPES OF ASTATINE | NEORX CORPORATION (US) | 1992-04-07 | — | — | US | disclosed |
| US-5057301-A | MODIFIED CELLULAR SUBSTRATES USED AS LINKERS FOR INCREASED CELL RETENTION OF DIAGNOSTIC AND THERAPEUTIC AGENTS | NEORX CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| US-5045303-A | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
| US-4885153-A | Radiohalogenated for proteins | NEORX CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0336364-A2 | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents | NEORX CORPORATION (US) | 1989-10-11 | — | — | EP | disclosed |
| EP-0203764-A2 | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | KMT2A 3647/4885MEN1 844/4885SMN1; SMN2 3838/4885 |
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | FOLH1, KLK3, FRS2 | KMT2A 706/4885MEN1 395/4885SMN1; SMN2 2554/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | KMT2A 3647/4885MEN1 844/4885SMN1; SMN2 3838/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | KMT2A 3946/4885MEN1 1001/4885SMN1; SMN2 4270/4885 |
| US-20170266327-A1 | RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS | PARP11, PARP1, PARP12 | KMT2A 917/4885MEN1 239/4885SMN1; SMN2 3675/4885 |
| US-10512700-B2 | Radiohalide-labeled targeted diagnostics and therapeutics | PARP11, PARP1, PARP12 | KMT2A 917/4885MEN1 239/4885SMN1; SMN2 3675/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | KMT2A 3647/4885MEN1 844/4885SMN1; SMN2 3838/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | KMT2A 1100/4885MEN1 258/4885SMN1; SMN2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.